Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab Long-Term Efficacy and Safety in Osteoarthritis
NCT00809354Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Feb 2009
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in osteoarthritis (OA) (5 arms), sponsored by Pfizer. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale Score at Week 16, Western Ontario and McMaster Universities Osteoarthritis Index Physical Function Subscale Score at Week 16 and 1 more. Started Feb 2009; status: terminated.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00809354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809354.